BiotechTube

Topiramate and Naltrexone

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcoholism

Conditions

Alcoholism

Trial Timeline

Oct 1, 2008 → Dec 1, 2010

NCT ID
NCT00769158

About Topiramate and Naltrexone

Topiramate and Naltrexone is a phase 1 stage product being developed by Johnson & Johnson for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00769158. Target conditions include Alcoholism.

What happened to similar drugs?

4 of 9 similar drugs in Alcoholism were approved

Approved (4) Terminated (1) Active (4)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
❌Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00769158Phase 1Completed

Competing Products

18 competing products in Alcoholism

See all competitors
ProductCompanyStageHype Score
acamprosateJohnson & JohnsonPre-clinical
26
TopiramateJohnson & JohnsonPhase 2
35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapyJohnson & JohnsonPhase 2
31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
40
topiramateJohnson & JohnsonPhase 2
35
Seroquel XRAstraZenecaApproved
43
Quetiapine fumarateAstraZenecaPhase 2
35
Acamprosate or NaltrexoneMerckApproved
43
Acamprosate + PlaceboMerckApproved
43
SCH 900435 + PlaceboMerckPhase 2
27
CP-866,087PfizerPhase 2
35
LevetiracetamUCBApproved
43
levetiracetamUCBPhase 2
35
Nalmefene + PlaceboLundbeckPhase 1
18
Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
29
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3
37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mgAlkermesPhase 3
37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mgAlkermesPhase 3
37